<DOC>
	<DOCNO>NCT00844480</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled trial zoledronic acid , 5mg , administer intravenously people suffer acute spinal cord fracture . The goal evaluate zoledronic acid prevent acute bone loss see population . Outcome measure include bone density determination one year period .</brief_summary>
	<brief_title>Efficacy Safety Zoledronic Acid Acute Spinal Cord Injury : Prevention Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Men woman 2 . Age 18 year old 3 . Spinal cord injury within 8 week study entry 4 . ASIA AIS A B 5 . Medically stable opinion physiatrist 6 . Able dexa perform 7 . Able return followup 6 12 month 1 . Vitamin D deficiency 2 . Hypocalcemia 3 . Renal insufficiency ( estimate creatinine clearance &lt; 30ml/min ) 4 . Abnormal thyroid hormone status 5 . Abnormal mental status 6 . Osteoporosis hip spine dexa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>spinal cord injury</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone loss</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>bisphosphonate</keyword>
</DOC>